Advertising Disclaimer
PEDIATRICS Vol. 96 No. 1 July 1995, pp. 14-17
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldstein, T. J.
Right arrow Articles by Peterson, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldstein, T. J.
Right arrow Articles by Peterson, C. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Ribavirin Therapy: Implementation of Hospital Guidelines and Effect on Usage and Cost of Therapy

Thomas J. Feldstein PharmD1, Jon L. Swegarden BS, RRT2, Gerald F. Atwood MD3, , Charles D. Peterson PharmD4

1 Department of Clinical Pharmacy, MeritCare Childrens Hospital, Fargo, ND, Department of Pharmacy Practice, North Dakota State University, Fargo, Children's Health Care-Minneapolis, MN
2 Department of Cardiopulmonary Services, MeritCare Childrens Hospital, Fargo, ND
3 Department of Pediatrics, MeritCare Childrens Hospital, Fargo, ND, Mcleod Regional Medical Center, Florence, SC
4 Department of Pharmacy Practice, North Dakota State University, Fargo

Objective. The American Academy of Pediatrics (AAP) recommends that ribavirin be reserved for infants who are severely ill and who are at high risk of morbidity and mortality, based on underlying clinical conditions. The purpose of this study was to evaluate current ribavirin use in our institution, implement hospital-specific guidelines for use, develop a prospective surveillance system to monitor ribavirin therapy, and evaluate the impact of these guidelines on subsequent use and cost of therapy.

Methods. Ribavirin use was compared with the recommendations of the AAP. Results were presented to the professional staff, and hospital guidelines were implemented. Ribavirin therapy was reevaluated in a 2-year period after hospital guidelines were implemented.

Results. In the initial evaluation period, only 67% of the ribavirin recipients met the AAP guidelines for use, and 19% received an inappropriate treatment regimen. The total cost and billed patient charges for ribavirin recipients who did not meet the guidelines for use in period 1 was $60 638 and $127 940, respectively. Over the next 2 years (period 2) after the implementation of hospital guidelines, the percentage of patients who received ribavirin decreased 35%, and approximately 96% of ribavirin recipients met the established criteria. Based on the decrease in the percentage of patients who received ribavirin in period 2 (41% versus 63%), the estimated cost avoidance and reduction in billed patient charges in period 2 was $55 540 and $117 334, respectively. This represents an estimated reduction in hospital costs and billed patient charges of $46 283 and $97 778 per 100 admissions for acute bronchiolitis.

Conclusions. Before the implementation of hospital guidelines for use, a substantial percent of patients received ribavirin not consistent with the recommendations of the AAP. Following the adoption of a modified version of the AAP guidelines for our institution and the use of a multidisciplinary surveillance system for monitoring ribavirin therapy, we observed a substantial decrease in the overall ribavirin use. This has resulted in a significant savings in terms of cost avoidance and reduced billed patient charges.

Submitted on August 16, 1993
Accepted on November 2, 1994


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
P. Checchia
Identification and management of severe respiratory syncytial virus
Am. J. Health Syst. Pharm., December 1, 2008; 65(23_Supplement_8): S7 - S12.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Subcommittee on Diagnosis and Management of Bronch
Diagnosis and Management of Bronchiolitis
Pediatrics, October 1, 2006; 118(4): 1774 - 1793.
[Abstract] [Full Text] [PDF]

Home page
 American Journal of Medical QualityHome page
B. J. BootsMiller, J. W. Yankey, S. D. Flach, M. M. Ward, T. E. Vaughn, K. F. Welke, and B. N. Doebbeling
Classifying the Effectiveness of Veterans Affairs Guideline Implementation Approaches
American Journal of Medical Quality, November 1, 2004; 19(6): 248 - 254.
[Abstract] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. J. Easton, J. B. Domachowske, and H. F. Rosenberg
Animal Pneumoviruses: Molecular Genetics and Pathogenesis
Clin. Microbiol. Rev., April 1, 2004; 17(2): 390 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. R. Wyde, D. K. Moore-Poveda, E. De Clercq, J. Neyts, A. Matsuda, N. Minakawa, E. Guzman, and B. E. Gilbert
Use of Cotton Rats to Evaluate the Efficacy of Antivirals in Treatment of Measles Virus Infections
Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1146 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. B. Domachowske and H. F. Rosenberg
Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment
Clin. Microbiol. Rev., April 1, 1999; 12(2): 298 - 309.
[Abstract] [Full Text] [PDF]